Clinical Trial Update: Epigenetic Biomarker for Osteosarcoma

View source ↗

Summary

This clinical trial update reports on an epigenetic biomarker study in osteosarcoma. It examines endpoints including histologic response, objective response rat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteosarcoma

Snippet

Sponsor: Peking University People's Hospital | Conditions: Histologic Response (Tumor Necrosis Rate), Objective Response Rate for Neoadjuvant Chemotherapy, ORR | Status: UNKNOWN